FDA Accepts Supplement Application for Dapagliflozin by Inventia
The FDA has accepted the supplemental application for dapagliflozin submitted by Inventia.
Asset / Drug
Drug and asset intelligence for Inventia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.